There is a growing need to shift from 'reactive' management driven by disease complications to 'proactive' care with the aim to prevent disease damages.

The VDZ-CDST scoring system has been developed and tested through post hoc analyses using data from over 2400 patients across multiple cohorts from studies conducted globally.

Découvrez nos débuts, plongez dans notre présent et laissez-vous inspirer par notre vision de l'avenir.

Apprenez-en davantage sur nos différents projets et collaborations, tous axés sur notre mission fondamentale : innover en gastro-entérologie afin que les patients puissent profiter pleinement de l'instant présent. 

Télécharger le pdf ici ou cliquer sur la vignette ci-dessous

Presentation, divided in the 3 main topics prof D’Haens shared with us:

During the 25 min of podcast Prof G D'Haens, Amsterdam and Prof Bossuyt, Imelda, discuss 2 main topics

Pharmaceutical class: Vedolizumab is a gut selective biological immunosuppressant 
Active compound: vedolizumab

SmPC: Click here for Entyvio 108 mg, solution for sub cutaneous injection
SmPC: click here for Entyvio 300 mg, solution for intravenous injection

Watch the testimonial videos of the UZ Leuven SBS-IF multi-disciplinary team and patients to learn their views on key priorities and challenges in the management of short bowel syndrome with intestinal failure (SBS-IF)

In Their Shoes is an around-the-clock immersive experience that integrates with the daily routine to deliver a visceral insight into patients’ lives.

An immersive simulation in which you become the patient – and experience what it is like to live with short bowel disease.